EXPORT CITATION

Chapter-12 Management of Age-related Macular Degeneration

BOOK TITLE: Recent Advances in Ophthalmology—9

Author
1. Hussain Nazimul
2. Dabir Supriya
3. Hussain Anjili
ISBN
9788184489613
DOI
10.5005/jp/books/11149_12
Edition
1/e
Publishing Year
2010
Pages
24
Author Affiliations
1. Al Zahra Pvt. Hospital, Sharjah/Dubai, UAE, Al Zahara Hospital, Sharjah, UAE, Al-Zahra Hospital, Shrajah, UAE, Al Zahra Pvt Hospital, Al Zahra Square, PO Box : 3499, Sharjah, UAE, Vitreoretinal Surgery Clinic, Aditya Jyot Eye Hospital, Mumbai, India, Al Zahra Hospital, PO Box Sharjah, UAE, Al Zahra Hospital, PO Box 3499 Sharjah, UAE, L.V. Prasad Eye Institute, Hyderabad, India, LV Prasad Eye Institute, Hyderabad, Smt. Kannuri Santhamma Retina, Vitreous Center, LV Prasad Eye Institute, Hyderabad, India, Al Zahra Hospital, Sharjah, UAE, Smt. Kanuri Santhamma Retina and Vitreous Centre, LV Prasad Eye Institute LV Prasad Marg, Banjara Hills Hyderabad, Al Zahra Pvt Hospital, Sharjah/Dubai, UAE
2. Aditya Jyot Eye Hospital Pvt Ltd, Major Parmeshwaran Road Opp. SIWS College, Gate No.3, Wadala, Mumbai-400031, India, Aditya Jyot Eye Hospital Pvt. Ltd., Major Parmeshwaran Road, Opp. SIWS College, Wadala, Mumbai, Aditya Jyot Eye Hospital, Mumbai, Maharashtra, India, Aditya Jyot Eye Hospital Pvt. Ltd, Plot No. 153, Road No.9, Major Parmeshwaran Road, Opp. SIWS College, Gate No.3, Wadala, Mumbai, India, Aditya Jyot Eye Hospital Pvt Ltd, Plot No 153, Road No 9, Major Parmeshwaran Road, Opp SIWS College, Gate No 3, Wadala, Mumbai-400031, Maharashtra, India, Narayana Nethralaya, Bengaluru, Karnataka, India, Aditya Jyoti Eye Hospital, Mumbai, Maharashtra, India
3. Sharjah, UAE
Chapter keywords

Abstract

Age-related macular degeneration is the leading cause of blindness in the world. For many patients, the visual impairment associated with AMD means a loss of independence, depression, increased financial concerns and the need to adapt to vision loss at a time when they are likely to be suffering from other debilitating conditions. Clinically, AMD is classified into the nonexudative “dry” or atrophic form and the exudative “wet” or neovascular form. More severe vision loss is typically associated with the “wet” form that occurs in about 10% of all patients with AMD but up to 20% of legal blindness from AMD is due to the “dry” form. However, recent advances in clinical research have led to better understanding of genetics and pathophysiology of AMD and discoveries of new therapies designed to treat and prevent different forms of AMD. Future may include combination approach that has potential to decrease the recurrence, progression and also improve efficacy besides providing additional blockade of the angiogenic cascade. In nutshell, with increasing life expectancy, we will face more patients with AMD searching for cost-effective approach yet functionally beneficial. Limited financial resources will force us to select the best and most effective therapy for our patients. One must also understand that present scientific evidence should allow to select therapies that can restore quality central vision and allow patients to experience the benefit of treatment.

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved